-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On March 14th, Shouyao Holdings, a new stock on the Science and Technology Innovation Board, opened for subscription.
The company is an enterprise focusing on the field of domestic small molecule innovative drugs
.
The company's issue price is 39.
90 yuan per share, with a reference industry price-earnings ratio of 35.
38 times
.
It is reported that the company's R&D pipeline covers key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as other important disease areas such as type II diabetes
.
At present, a full-process innovative drug integrating AI drug design, medicinal chemistry, target biology, pharmacology, pharmacodynamics, pharmacokinetics, toxicology, pharmacy research, clinical medicine, translational medicine research, and quality management has been formed R&D system
.
In terms of products under research, the company has developed 23 new drugs under research with independent intellectual property rights, of which 17 have entered clinical research, including 6 products under research that are completely independently developed and 11 products under research that are jointly developed (The company is responsible for the discovery and screening of preclinical drug candidates.
After the completion of the small-scale synthesis process handover, the partner will conduct follow-up GLP toxicology experiments, clinical research and development and commercialization.
Both parties share intellectual property rights, and the company enjoys milestones according to the agreement payment and commercialization rights)
.
At present, the company's two pipelines have entered clinical phase III, and the research and development progress of many products is at the forefront in China
.
Among them, SY-707 can be applied for conditional listing according to the clinical situation after the completion of clinical phase II.
This product is the second-generation ALK kinase inhibitor independently developed by the company, which is used for the treatment of advanced ALK-positive non-small cell lung cancer.
It belongs to domestic and overseas Innovative drugs that are not yet on the market
.
SY-3505 is the first domestic third-generation ALK inhibitor to enter clinical research in China.
It has obtained the clinical trial notice on July 2, 2019, and is currently in the phase I clinical trial stage
.
The drug still has obvious inhibitory effect on common drug-resistant mutants of first- and second-generation ALK inhibitors, and is an innovative drug that has not been marketed at home and abroad
.
In addition, SY-1530 is a highly selective and irreversible BTK kinase inhibitor with a new structure independently developed by the company, which is an innovative drug that has not been marketed at home and abroad
.
The drug is intended to be used for the treatment of relapsed and refractory non-Hodgkin lymphoma (NHL) and other B cell-derived malignancies.
It has obtained clinical approval on August 25, 2016, and has now entered phase II clinical trials for the treatment of Mantle cell lymphoma (MCL) in non-Hodgkin lymphoma
.
From the perspective of R&D investment, in 2018, 2019, 2020 and the first half of 2021, the company's R&D investment was 31.
8365 million yuan, 43.
9103 million yuan, 85.
0327 million yuan and 65.
6151 million yuan respectively
.
During the reporting period, the company was still in the drug R&D and clinical stage, so the R&D investment was relatively high
.
It is worth mentioning that, as First Pharmaceutical Holdings has no products on the market, it has not generated any revenue from drug sales and is still in a state of loss
.
Small molecule targeted antitumor drugs have a broad market
.
According to Frost & Sullivan's analysis, it is estimated that the global market size of targeted anti-tumor small molecule drugs will reach 73.
8 billion US dollars.
The catalogue is constantly being adjusted, the coverage of small molecule targeted drugs continues to increase, at the same time, doctors and patients have a deeper understanding of small molecule targeted drugs, the market acceptance is gradually improving, and more and more imported and domestic innovative small molecule targeted drugs are available.
Driven by favorable factors such as the approval of marketing in China, the small molecule targeted antitumor drug market in China will develop rapidly in the next few years
.
It is reported that after deducting the issuance costs, the funds raised by the company will be used for innovative drug research and development projects, new drug research and development and industrialization bases, and supplementary working capital.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The company is an enterprise focusing on the field of domestic small molecule innovative drugs
.
The company's issue price is 39.
90 yuan per share, with a reference industry price-earnings ratio of 35.
38 times
.
It is reported that the company's R&D pipeline covers key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as other important disease areas such as type II diabetes
.
At present, a full-process innovative drug integrating AI drug design, medicinal chemistry, target biology, pharmacology, pharmacodynamics, pharmacokinetics, toxicology, pharmacy research, clinical medicine, translational medicine research, and quality management has been formed R&D system
.
In terms of products under research, the company has developed 23 new drugs under research with independent intellectual property rights, of which 17 have entered clinical research, including 6 products under research that are completely independently developed and 11 products under research that are jointly developed (The company is responsible for the discovery and screening of preclinical drug candidates.
After the completion of the small-scale synthesis process handover, the partner will conduct follow-up GLP toxicology experiments, clinical research and development and commercialization.
Both parties share intellectual property rights, and the company enjoys milestones according to the agreement payment and commercialization rights)
.
At present, the company's two pipelines have entered clinical phase III, and the research and development progress of many products is at the forefront in China
.
Among them, SY-707 can be applied for conditional listing according to the clinical situation after the completion of clinical phase II.
This product is the second-generation ALK kinase inhibitor independently developed by the company, which is used for the treatment of advanced ALK-positive non-small cell lung cancer.
It belongs to domestic and overseas Innovative drugs that are not yet on the market
.
SY-3505 is the first domestic third-generation ALK inhibitor to enter clinical research in China.
It has obtained the clinical trial notice on July 2, 2019, and is currently in the phase I clinical trial stage
.
The drug still has obvious inhibitory effect on common drug-resistant mutants of first- and second-generation ALK inhibitors, and is an innovative drug that has not been marketed at home and abroad
.
In addition, SY-1530 is a highly selective and irreversible BTK kinase inhibitor with a new structure independently developed by the company, which is an innovative drug that has not been marketed at home and abroad
.
The drug is intended to be used for the treatment of relapsed and refractory non-Hodgkin lymphoma (NHL) and other B cell-derived malignancies.
It has obtained clinical approval on August 25, 2016, and has now entered phase II clinical trials for the treatment of Mantle cell lymphoma (MCL) in non-Hodgkin lymphoma
.
From the perspective of R&D investment, in 2018, 2019, 2020 and the first half of 2021, the company's R&D investment was 31.
8365 million yuan, 43.
9103 million yuan, 85.
0327 million yuan and 65.
6151 million yuan respectively
.
During the reporting period, the company was still in the drug R&D and clinical stage, so the R&D investment was relatively high
.
It is worth mentioning that, as First Pharmaceutical Holdings has no products on the market, it has not generated any revenue from drug sales and is still in a state of loss
.
Small molecule targeted antitumor drugs have a broad market
.
According to Frost & Sullivan's analysis, it is estimated that the global market size of targeted anti-tumor small molecule drugs will reach 73.
8 billion US dollars.
The catalogue is constantly being adjusted, the coverage of small molecule targeted drugs continues to increase, at the same time, doctors and patients have a deeper understanding of small molecule targeted drugs, the market acceptance is gradually improving, and more and more imported and domestic innovative small molecule targeted drugs are available.
Driven by favorable factors such as the approval of marketing in China, the small molecule targeted antitumor drug market in China will develop rapidly in the next few years
.
It is reported that after deducting the issuance costs, the funds raised by the company will be used for innovative drug research and development projects, new drug research and development and industrialization bases, and supplementary working capital.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
